01 January 2008
Compound Salvia droplet pill, a traditional Chinese medicine, for the treatment of unstable angina pectoris: a systematic review
Zhang Junhua, Shang Hongcai, Gao Xiumei, Zhang Boli, Xiang Yaozu, Cao Hongbo, Wang Hui, Ren MingMed Sci Monit 2008; 14(1): RA1-7 :: ID: 636050
Abstract
Compound Salvia droplet pill (CSDP) has been frequently used for patients with angina pectoris in China. However, the efficacy and safety of CSDP for unstable angina pectoris (UA) have not been systematically evaluated. The aim was to assess the efficacy and safety of CSDP for UA and provide information for current practice or future research. An extensive search was performed in Jan 2007 which included MEDLINE, EMBASE, Chinese Biomedical Database (CBM), and the Cochrane Center Controlled Trials Register. Randomized controlled trials (RCTs) about CSDP for UA were included irrespective of language. The main comparisons was CSDP plus current western drugs compared with western drugs alone. The quality of each trial was assessed according to criteria from the Cochrane Reviewers' Handbook. Statistical software (RevMan 4.2) provided by the Cochrane Collaboration was applied. Seventeen RCTs were included in this review. The quality of the trials was low. Statistical analysis of the results showed that CSDP plus western routine drugs compared with routine drugs alone had significant effect on relieving angina symptoms (P<0.00001, pooled RR=1.23, 95%CI: 1.16-1.30) and improving ECG (P<0.00001, pooled RR=1.34, 95%CI: 1.23-1.46). Some trials' data suggest that CSDP can also improve hemorheology and blood lipid level. CSDP had a significant effect for treatment of UA with few adverse events. However, the evidence is not reliable enough because of the low quality of the methodology of the included trials. To produce good evidence, high-quality clinical trials are needed.
Keywords: Salvia - adverse effects, Safety, Phytotherapy, Lipids - blood, Hemorheology, Drugs, Chinese Herbal - therapeutic use, Angina, Unstable - drug therapy
Editorial
01 March 2024 : Editorial
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-ThalassemiaDOI: 10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
In Press
18 Mar 2024 : Clinical Research
Sexual Dysfunction in Women After Tibial Fracture: A Retrospective Comparative StudyMed Sci Monit In Press; DOI: 10.12659/MSM.944136
21 Feb 2024 : Clinical Research
Potential Value of HSP90α in Prognosis of Triple-Negative Breast CancerMed Sci Monit In Press; DOI: 10.12659/MSM.943049
22 Feb 2024 : Review article
Differentiation of Native Vertebral Osteomyelitis: A Comprehensive Review of Imaging Techniques and Future ...Med Sci Monit In Press; DOI: 10.12659/MSM.943168
23 Feb 2024 : Clinical Research
A Study of 60 Patients with Low Back Pain to Compare Outcomes Following Magnetotherapy, Ultrasound, Laser, ...Med Sci Monit In Press; DOI: 10.12659/MSM.943732
Most Viewed Current Articles
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952